PFI-1, a highly selective protein interaction inhibitor, targeting BET Bromodomains.

PFI-1, a highly selective protein interaction inhibitor, targeting BET Bromodomains.

Bromo and extra terminal (BET) proteins (BRD2, BRD3, BRD4, and BRDT) are transcriptional regulators required for efficient expression of several growth promoting and antiapoptotic genes as well as for cell-cycle progression. BET proteins are recruited on transcriptionally active chromatin via their...

Descrizione completa

Dettagli Bibliografici
Autori principali:	Picaud, S, Da Costa, D, Thanasopoulou, A, Filippakopoulos, P, Fish, P, Philpott, M, Fedorov, O, Brennan, P, Bunnage, M, Owen, DR, Bradner, J, Taniere, P, O'Sullivan, B, Müller, S, Schwaller, J, Stankovic, T, Knapp, S
Natura:	Journal article
Lingua:	English
Pubblicazione:	2013

Documenti analoghi

Developing chemical probes for the BET bromodomains
di: Hewings, D, et al.
Pubblicazione: (2012)

The design and synthesis of 5-and 6-isoxazolylbenzimidazoles as selective inhibitors of the BET bromodomains
di: Hay, D, et al.
Pubblicazione: (2013)

Chemical probes for bromodomains outside the BET family
di: Brennan, P, et al.
Pubblicazione: (2013)

Selective inhibition of BET bromodomains.
di: Filippakopoulos, P, et al.
Pubblicazione: (2010)

Selective inhibition of BET bromodomains.
di: Filippakopoulos, P, et al.
Pubblicazione: (2010)

Benzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the BET family.
di: Filippakopoulos, P, et al.
Pubblicazione: (2012)

Benzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the BET family
di: Filippakopoulos, P, et al.
Pubblicazione: (2012)

RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain.
di: Picaud, S, et al.
Pubblicazione: (2013)

RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain
di: Picaud, S, et al.
Pubblicazione: (2013)

Small-molecule bromodomain inhibitors for cancer therapy
di: Qi, J, et al.
Pubblicazione: (2010)

Promiscuous targeting of bromodomains by Bromosporine identifies BET proteins as master regulators of primary transcription response in leukemia
di: Picaud, S, et al.
Pubblicazione: (2016)

Evaluation of linker length effects on a BET bromodomain probe
di: Traquete, R, et al.
Pubblicazione: (2019)

3,5-Dimethylisoxazoles inhibit the bromodomain-histone protein-protein interaction
di: Hewings, D, et al.
Pubblicazione: (2012)

Bromodomain-peptide displacement assays for interactome mapping and inhibitor discovery.
di: Philpott, M, et al.
Pubblicazione: (2011)

Bromodomain-peptide displacement assays for interactome mapping and inhibitor discovery.
di: Philpott, M, et al.
Pubblicazione: (2011)

Discovery and Optimization of Small-Molecule Ligands for the CBP/p300 Bromodomains
di: Hay, D, et al.
Pubblicazione: (2014)

Synthesis and biological investigation of (+)-JD1, an organometallic BET bromodomain inhibitor
di: Hassell-Hart, S, et al.
Pubblicazione: (2019)

3,5-dimethylisoxazoles act as acetyl-lysine-mimetic bromodomain ligands.
di: Hewings, D, et al.
Pubblicazione: (2011)

Developing small molecule inhibitors of the CREBBP bromodomain-histone interaction
di: Rooney, T, et al.
Pubblicazione: (2012)

Selective targeting of the BRG/PB1 bromodomains impairs embryonic and trophoblast stem cell maintenance.
di: Fedorov, O, et al.
Pubblicazione: (2015)

Identification of a chemical probe for bromo and extra C-terminal bromodomain inhibition through optimization of a fragment-derived hit.
di: Fish, P, et al.
Pubblicazione: (2012)

[1,2,4]triazolo[4,3-a]phthalazines: inhibitors of diverse bromodomains.
di: Fedorov, O, et al.
Pubblicazione: (2014)

Interactome rewiring following pharmacological targeting of BET bromodomains
di: Lambert, J-P, et al.
Pubblicazione: (2018)

BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability
di: Jennings, L, et al.
Pubblicazione: (2018)

The bromodomain interaction module.
di: Filippakopoulos, P, et al.
Pubblicazione: (2012)

The bromodomain interaction module
di: Filippakopoulos, P, et al.
Pubblicazione: (2012)

3,5-dimethylisoxazoles act as acetyl-lysine-mimetic bromodomain ligands
di: Hewings, D, et al.
Pubblicazione: (2011)

Stimulation of Hepatic Apolipoprotein A-I Production by Novel Thieno-Triazolodiazepines: Roles of the Classical Benzodiazepine Receptor, PAF Receptor, and Bromodomain Binding.
di: Kempen, H, et al.
Pubblicazione: (2013)

Bromodomains as therapeutic targets.
di: Muller, S, et al.
Pubblicazione: (2011)

Chemical probes and inhibitors of bromodomains outside the BET family
di: Moustakim, M, et al.
Pubblicazione: (2016)

Targeting bromodomains: epigenetic readers of lysine acetylation.
di: Filippakopoulos, P, et al.
Pubblicazione: (2014)

BET bromodomain inhibitors PFI-1 and CPI-203 suppress the development of follicular lymphoma via regulating Wnt/β-catenin signaling
di: Min Bai, et al.
Pubblicazione: (2024-03-01)

Discovery of BET bromodomain inhibitors and their role in target validation
di: Mueller, S, et al.
Pubblicazione: (2014)

Dissecting the Role of BET Bromodomain Proteins BRD2 and BRD4 in Human NK Cell Function
di: Cribbs, AP, et al.
Pubblicazione: (2021)

Dual kinase-bromodomain inhibitors for rationally designed polypharmacology.
di: Ciceri, P, et al.
Pubblicazione: (2014)

Corrigendum: Dual kinase-bromodomain inhibitors for rationally designed polypharmacology.
di: Ciceri, P, et al.
Pubblicazione: (2014)

Optimization of 3,5-dimethylisoxazole derivatives as potent bromodomain ligands.
di: Hewings, D, et al.
Pubblicazione: (2013)

Dissecting the Role of BET Bromodomain Proteins BRD2 and BRD4 in Human NK Cell Function
di: Adam P. Cribbs, et al.
Pubblicazione: (2021-02-01)

BET bromodomain proteins regulate enhancer function during adipogenesis
di: Brown, Jonathan D., et al.
Pubblicazione: (2018)

Inhibition of BET Bromodomain Targets Genetically Diverse Glioblastoma
di: Cheng, Z, et al.
Pubblicazione: (2013)